Neurological Surgery 脳神経外科50巻3号

2022年05月発行

特集 一生使える頭蓋底外科の“知”と“技”—〔特別付録Web動画付き〕 Ⅱ頭蓋底外科手術に必要な解剖・生理・病理の知識

髄膜腫WHO grade 1/2/3の最新知見

著者： 大宅宗一¹

所属機関： ¹埼玉医科大学総合医療センター脳神経外科

ページ範囲：P.564 - P.571

Point
・髄膜腫のWHO分類に分子診断が重要な役割を果たすようになってきている．
・外科治療は依然として髄膜腫治療における第一選択である．
・外科治療が困難なWHO grade 2/3髄膜腫への新規治療法の開発が進んでいる．

参考文献

1）Baumgarten P, et al：Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. Acta Neuropathol 132：479-481, 2016

2）Vaubel RA, et al：Meningiomas with rhabdoid features lacking other histologic features of malignancy：a study of 44 cases and review of the literature. J Neuropathol Exp Neurol 75：44-52, 2016

3）Shankar GM, Santagata S：BAP1 mutations in high-grade meningioma：implications for patient care. Neuro Oncol 19：1447-1456, 2017

4）Kirches E, et al：Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. Acta Neuropathol 142：873-886, 2021

5）Agnihotri S, et al：Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nat Commun 8：186, 2017　doi：10.1038/s41467-017-00174-7

6）Smith MJ, et al：Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet 45：295-298, 2013

7）Sahm F, et al：DNA methylation-based classification and grading system for meningioma：a multicentre, retrospective analysis. Lancet Oncol 18：682-694, 2017

8）Goldbrunner R, et al：EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23：1821-1834, 2021

9）日本脳ドック学会 脳ドックのガイドライン2019改訂委員会（編）：脳ドックのガイドライン 2019 改訂第5版．響文社，札幌，2019, pp. 75-77

10）National Comprehensive Cancer Network（NCCN）：NCCN Guidelines for Central Nervous System Cancers.　http://www.nccn.org/（2022年1月28日アクセス）

11）Behbahani M, et al：A prospective study of the natural history of incidental meningioma-Hold your horses! Neurooncol Pract 6：438-450, 2019

12）Oya S, et al：The natural history of intracranial meningiomas：clinical article. J Neurosurg 114：1250-1256, 2011

13）Schwartz TH, McDermott MW：The Simpson grade：abandon the scale but preserve the message. J Neurosurg 135：488-495, 2021

14）Yang C, et al：Transsphenoidal versus transcranial approach for treatment of tuberculum sellae meningiomas：a systematic review and meta-analysis of comparative studies. Sci Rep 9：4882, 2019　doi：10.1038/s41598-019-41292-0

15）Lee JH, et al：Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma. J Neurosurg 105：60-64, 2006

16）Hashimoto N, et al：Slower growth of skull base meningiomas compared with non-skull base meningiomas based on volumetric and biological studies. J Neurosurg 116：574-580, 2012

17）Sheehan JP, et al：Gamma Knife radiosurgery for posterior fossa meningiomas：a multicenter study. J Neurosurg 122：1479-1489, 2015

18）Oh HJ, et al：Hypofractionated stereotactic radiosurgery for large-sized skull base meningiomas. J Neurooncol 149：87-93, 2020

19）Patibandla MR, et al：Stereotactic radiosurgery of central skull base meningiomas-volumetric evaluation and long-term outcomes. World Neurosurg 108：176-184, 2017

20）Combs SE, et al：Clinical outcome after high-precision radiotherapy for skull base meningiomas：pooled data from three large German centers for radiation oncology. Radiother Oncol 127：274-279, 2018

21）National Comprehensive Cancer Network：NCCN：NCCN Guidelines：Central Nervous System Cancers.　http://www.nccn.org/（Accessed 26 Jan 2022）

22）Marchetti M, et al：Multisession radiosurgery for perioptic meningiomas：medium-to-long term results from a CyberKnife cooperative study. J Neurooncol 143：597-604, 2019

23）Oya S, et al：Effect of adjuvant radiotherapy after subtotal resection for WHO grade I meningioma：a propensity score matching analysis of the Brain Tumor Registry of Japan. J Neurooncol 153：351-360, 2021

24）Schipmann S, et al：Is the Simpson grading system applicable to estimate the risk of tumor progression after microsurgery for recurrent intracranial meningioma? World Neurosurg 119：e589-e597, 2018　doi：10.1016/j.wneu.2018.07.215

25）Rydzewski NR, et al：Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma. Cancer 124：734-742, 2018

26）Rogers L, et al：Intermediate-risk meningioma：initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129：35-47, 2018

27）Weber DC, et al：Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma：a phase-Ⅱ parallel non-randomized and observation study（EORTC 22042-26042）. Radiother Oncol 128：260-265, 2018

28）Sughrue ME, et al：Outcome and survival following primary and repeat surgery for World Health Organization Grade Ⅲ meningiomas. J Neurosurg 113：202-209, 2010

29）Rogers CL, et al：High-risk meningioma：initial outcomes from NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys 106：790-799, 2020

30）Kaley T, et al：Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma：a RANO review. Neuro Oncol 16：829-840, 2014

31）Huang RY, et al：Proposed response assessment and endpoints for meningioma clinical trials：report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol 21：26-36, 2019

32）Takai S, et al：Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up. Neuro Oncol 24：90-98, 2022

33）Juratli TA, et al：Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget 8：109228-109237, 2017

34）Bi WL, et al：Genomic landscape of high-grade meningiomas. NPJ Genom Med 2：15, 2017　doi：10.1038/s41525-017-0014-7

35）Magill ST, et al：Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nat Commun 11：4803, 2020　doi：10.1038/s41467-020-18582-7

36）Oya S, et al：Intraoperative quantification of meningioma cell proliferation potential using rapid flow cytometry reveals intratumoral heterogeneity. Cancer Med 8：2793-2801, 2019